Conference
1528PD Initial results of BMS-986012, a first-in-class fucosyl-GM1 mAb, in combination with nivolumab, in pts with relapsed/refractory (rel/ref) small-cell lung cancer (SCLC)
Authors
Chu QS-C; van Herpen C; Leighl NB; Markman B; Clarke S; Juergens RA; Basciano P; Lathers D; Tannenbaum-Dvir S; Urbanska K
Volume
28
Publisher
Elsevier
Publication Date
September 1, 2017
DOI
10.1093/annonc/mdx386.002
Conference proceedings
Annals of Oncology
ISSN
0923-7534